Supporting Standards Development for Regenerative Medicine Therapies
On September 27, 2017, the U.S. Food and Drug Administration (FDA) awarded a one-year contract to Nexight Group and SCB to engage with experts to recommend processes and outline a strategic plan for developing standards in regenerative medicine and advanced therapies. The Nexight-SCB team will develop a landscape report that outlines business needs, gaps in standards, and promising therapy areas for standards application; host three webinars for community stakeholders; and develop processes and criteria for identifying, prioritizing, and assessing the feasibility of standards that will have a high impact on the quality, safety, and cost-benefit of standards’ needs.
This work will create a foundation that allows industry, regulatory authorities, and other stakeholders to reduce barriers to regenerative medicine research and product development and accelerate the market readiness of these life-changing medical treatments.
September 2017-September 2018
Webinar on the need for standards in regenerative medicine
More than 60 of you joined us on a webinar on the Need for Standards in Regenerative Medicine held Tuesday, December 12, 2017. We heard from Heidi Hagen, the Chief Strategy Officer at Vineti, and Anthony Ratcliffe, Chief Executive Officer of Synthasome, about how the development of standards influenced the work in their fields of regenerative medicine.
If you weren’t able to join us, you may view the webinar or slides at the following links:
We will hold the next webinar on the existing standards landscape in March 2018. Keep an eye out for a save-the-date email and invitation!
help identify existing standards and gaps
Thank you to those who provided input to identify existing standards and areas where standards are needed in the field of regenerative medicine. This input has been developed into a landscape analysis report on regenerative medicine therapy standards. Once the report has been reviewed by the FDA, it will be shared on this website.